Creabilis Appoints Dr. Eliot Forster as its New Chief Executive Officer

04-Oct-2010 - Luxembourg

Creabilis SA announced the appointment of Eliot Forster as its new Chief Executive Officer. Dr Forster brings to Creabilis significant drug development experience having brought a number of molecules to market.

Dr Forster has close to 20 years industry experience in biotechnology and pharmaceutical companies. He was most recently the CEO of Solace Pharmaceuticals, a US-based biotech. Prior joining Solace, Dr Forster was Head of EU Development and of Development Operations in the EU & Asia at Pfizer. During his career at Pfizer Dr Forster was integral to bringing a number of drugs to market, including Celebrex(R) (celecoxib), Bextra(R) (valcecoxib) and Relpax(R) (eletriptan).

Dr Forster holds a PhD from Liverpool University and an M.B.A. from Henley Management College. He has held a number of Non-Executive Director roles in the biotech sector and is an advisor to the UKTI Life Sciences Strategy Board.

Other news from the department people

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance